KRAS and neoplasm: Another study showed that pembrolizumab combined with pemetrexed plus carboplatin chemotherapy effectively controlled the disease, and patients continued to reduce the lesion 5 months after stopping treatment due to adverse events, despite KRAS G12D mutation positive and PD-L1 tumor proportion score (TPS) of less than 1% (27).